ATEA AT-03A-017

Brief description of study

Phase 3 study with screening, treatment, follow-up and extended follow up periods. Participants enrolled for up to 60 days. compare the effects, good or bad, of bemnifosbuvir versus placebo, on patients with mild to moderate COVID-19 who are not hospitalized. Participants will have blood tests, influenza tests, covid tests, physicals

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Medical Research
Age: - 99 Years
Gender: All

TBD

Updated on 09 Mar 2024. Study ID: 855008

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).